Area Medical Center Vienna, Eli Lilly & Company, Austria.
Curr Mol Pharmacol. 2008 Nov;1(3):270-2. doi: 10.2174/1874467210801030270.
Weight gain, diabetes, and changes in serum lipid profiles have been reported during treatment with typical and atypical antipsychotics. An association between diabetes and psychotic disorders was described long before the introduction of pharmacological agents for the treatment of schizophrenia. Several theories have been proposed to explain the baseline weight increase and metabolic disturbances in schizophrenia. Some studies suggest that increased food intake may improve psychotic symptoms in patients with schizophrenia but there have been conflicting results. Available clinical and basic research findings are discussed to evaluate the hypothesis that increased food intake may decrease sensitivity to dopamine signaling in the striatum. More research is needed to evaluate this potential link. However, basic animal research and evolutionary approaches can provide insights into metabolic disturbances associated with schizophrenia.
在使用典型和非典型抗精神病药物治疗期间，已报告体重增加、糖尿病和血清脂质谱变化。在用于治疗精神分裂症的药物问世之前，就已经描述了糖尿病与精神障碍之间的关联。已经提出了几种理论来解释精神分裂症患者的基线体重增加和代谢紊乱。一些研究表明，增加食物摄入可能会改善精神分裂症患者的精神病症状，但结果存在冲突。讨论了现有的临床和基础研究结果，以评估增加食物摄入可能降低纹状体多巴胺信号敏感性的假设。需要进一步的研究来评估这种潜在的联系。然而，基础动物研究和进化方法可以深入了解与精神分裂症相关的代谢紊乱。
